While presenting the results of the EPID Registry in previous publications 13, 14 , we indicated too low use of antithrombotic prophylaxis in Polish inter nal wards in high-risk patients. The present analysis evaluates the correctness of prophylaxis use in patients from inter nal medicine wards similar to the MEDENOX population.
PATIENTs ANd mEThOds The EPID Registry was an uncontrolled observational study involving 58 inter nal medicine wards from the whole Poland. 53 centers (91%) were localized in municipal or provincial hospitals and 5 in academic hospitals. In 41 centers (71%) specialist wards or separate intensive care rooms are located. Centers participating in the registry every month send information on the next 10 patients who fulfilled the study inclusion criteria. In accordance with the exclusion criteria, patients receiving chronic antithrombotic therapy because of atrial fibrillation, heart valve prothesis implantation, acute coronary syndrome or VTE do not qualify for the registry. Patients hospitalized for diagnosed de novo VTE who require anticoagulant therapy were also excluded from the study. Data were collected on a standardized questionnaire (Patient's Observation Card), available on the www page. Information on the main cause of admission and concomitant diseases was provided in the registry; risk factors of VTE occurrence were also evaluated. Subsequently, physicians participating in the registry provided the data on their decision about use of antithrombotic prophylaxis, its type and duration. The choice and use of the therapeutic agent were independent of the decision about the patient's qualification to the study; the used therapy is consistent with the accepted medical practice. If prophylaxis was not used, physicians participating in the registry were asked to specify reasons for such a decision. The last observation of the patient included to the registry was recorded on the day of discharge -a physician assesses occurrence of hemo rrhagic events associated with antithrombotic prophylaxis. According to the rules of non-interventional study, the protocol did not suggest specific management regarding the use and type of antithrombotic prophylaxis for registry participants. The study was performed in accordance with the principles of the Declaration of Helsinki, especialdepartments. 3 In this study a 64% relative risk reduction in VTE occurrence in the group of patients receiving 40 mg of enoxaparin compared to the placebo group, with the number needed to treat of 10, was observed. Innovative, at that time, inclusion criteria -including the population of patients with New York Heart Association III and IV heart failure, respiratory failure and acute rheumatic or inflammatory disease and an additional risk factor -became a model of antithrombotic prophylaxis in patients hospitalized in nonsurgical wards. The inclusion criteria of the MEDENOX study were subsequently used in the management guidelines indicating the necessity of antithrombotic prophylaxis with the highest level of recommendation. [4] [5] [6] [7] In subsequent post-hoc analyses the benefits of prophylaxis to all subpopulations of the MEDENOX study were confirmed 8 and a beneficial outcome of pharmacoeconomic analysis of the use of antithrombotic prophylaxis was shown.
9 The effectiveness and safety of antithrombotic prophylaxis in populations similar to the MEDENOX were confirmed in subsequent trials with dalteparin, 10 fondaparinux 11 and fraxiparine. 12 The studied para meters were presented as mean and 95% confidence inter val (95% CI). Qualitative variables were compared with the χ2 test. A value p <0.05 was regarded as statistically significant.
REsuLTs Pharmaco logical prophylaxis of VTE was used in 63% of cases. Depending on the main cause of hospital admission, its frequency varied between 52-69% (TAbLE 1) . Prophylaxis was administered on average for 8.1 days (95% CI: 7.8-8.4), with a mean duration of hospitalization in the prophylaxis group of 10.5 days (95% CI: 10.0-11.1).
In the group of patients admitted to intensive care units, prophylaxis was administered in 81% of cases; whereas in inter nal departmentsin 58% of cases (p <0.0001). Frequency of prophylaxis in academic centers was 68%, while in municipal and provincial hospitals this percentage was 62% (p = 0.01).
According to the participants, prophylaxis was not administered in 495 cases (9.5%) due to a risk of hemo rrhagic complications, most commonly gastrointestinal diseases (38%), central nervous system diseases (19%) and hemato logical disorders (14%).
From the total number of 4751 patients without contraindications to antithrombotic prophsylaxis, physicians did not see indications for its administration in 1431 patients (27% of whole population).
In the majority of cases where pharmaco logical antithrombotic prophylaxis was used low-molecular-weight heparins were administered (93%); standard heparin (2%), acenocoumarol (3%) and physical methods (2%) were implemented with a lower frequency. Amongst low-molecular-weight heparins, enoxaparin was administered in 89% of patients and nadroparin in 10%. In the group of 2804 patients who received enoxaparin, 52% received a dose of 40 mg/day, 44% -a higher dose, and 4% of patients received a dose of 20 mg/day. Daily dose distribution of low-molecular-weight heparins used as primary prevention of VTE is presented in FIGuRE 1.
Significant differences in the frequency of antithrombotic prophylaxis use between particular provinces were observed -the percentage of patients receiving prophylaxis varied between 35-89% (TAbLE 2 and FIGuRE 2). However, unequivocal time trend findings in the frequency of antithrombotic prophylaxis use in subsequent years of the registry were not observed (TAbLE 3) . 22 cases of hemo rrhagic complications (0.8%) were noted in the group receiving antithrombotic prophylaxis. Intracranial bleedings and deaths from bleedings were not observed. However, 3 patients from the bleeding group died, including -1 because of heart failure, 1 of lung cancer and 1 because of suspected pulmonary embolism. Autopsy was not performed in any of the cases. Gastrointestinal bleeding was observed in 8 cases, hematuria -in 5, and hemo ptysis in 4 patients. Hematoma involving the abdominal wall ly in the area of respecting the confidentiality of personal data of participants.
According to the accepted inclusion and exclusion criteria, 14,707 patients were enrolled to the EPID Registry in the period from August 2002 to May 2006. The study group, analyzed for the purpose of this publication, consisted of 5,246 patients (mean age -71 years, 95% CI: 70.6-71.4 years, 48% women, 52% men), which constituted 31% of hospitalizations in the EPID Registry. Patients aged >40 hospitalized because of heart failure, acute respiratory tract disease and acute infectious disease, rheumatic disease or inflammatory bowel disease, with an additional risk factor of VTE -age >75 years, malignant disease, past VTE, obesity, varicose veins, hormonal therapy, chronic respiratory insufficiency or chronic heart failure were qualified for the study. The profile of the VTE risk in the study group corresponded to the population of the MEDENOX study, which is a commonly accepted indication for pharmaco logical antithrombotic prophylaxis. 23% of patients were admitted to intensive care units, 77% were hospitalized in inter nal wards. 91% of patients were hospitalized in municipal and provincial hospitals, 9% -in academic centers. The mean duration of hospital stay was 10.1 (95% CI: 9.7-10.5) days. The geographical diversity of the frequency of antithrombotic prophylaxis use is strikingsome provinces approach optimal values, whilst in others only a 1/3 of patients with indications receive prophylaxis according to the guidelines.
Difficulties in reliable evaluation of the effectiveness and direct results of prophylaxis discontinuation are registry limitations. However, extrapolating data from the MEDENOX study, where the frequency of proximal lower extremity deep venous thrombosis was 5% and the frequency of episodes of pulmonary embolism was 1% in the placebo group, it can be expected that in the group of 1431 patients without indications for prophylaxis 71 cases of venous thrombosis and 14 cases of pulmonary embolism occurred. Assuming that mortality for pulmonary embolism is about 19%, it can be supposed that 2 patients could have died from this.
In Poland, antithrombotic prophylaxis is performed using low-molecular-weight heparins. This is in line with clinical practice in the European countries, but different from the management in the USA, where standard heparin is subcutaneously injected 2 or 3 times a day.
22 Meta-analysis of randomized studies comparing prophylaxis with low-molecular-weight heparins and standard heparin showed a similar effectiveness, but greater safety, manifested by a lower rate of serious bleedings in the former group. 23 Recently published retrospective effectiveness analysis of prophylaxis with enoxaparin and standard heparin showed a 74% risk reduction in thromboembolic complications during use of enoxaparin compared to standard heparin. 24 Moreover, prophylaxis with low-molecular-weight heparins have a better safety profile, especially in elderly patients.
25
Prophylaxis with low-molecular-weight heparins is in general calculation less expensive for a hospital, despite higher costs of these agents. 26 Looking critically at the number of doses taken by the registry participants it can be suspected that in some cases VTE prophylaxis is mistaken with antithrombotic therapy or systemic embolism prophylaxis. An indirect indication for this and retroperitoneal space was observed in 1 case. Bleedings at sites of intravenous injections were reported twice. There was one subcutaneous hematoma at the site of injection. Epistaxis and gingival bleeding were also observed only in 1 subject.
dIsCussION Despite unequivocal expert guidelines and its confirmed unquestionable medical and pharmacoeconomic benefits antithrombotic prophylaxis is rarely used in the population of patients hospitalized in nonsurgical wards. 15 On the basis of evaluation of 708 patients from inter nal medicine departments in Paris, Bergman et al. demonstrated that only 33% of them received antithrombotic prophylaxis with low-molecular-weight heparins. 16 Ageno et al. showed that in a small group of 112 patients from 2 Italian inter nal medicine departments, only 46% of subjects from the high-risk group received prophylaxis. 17 Among 1894 patients at increased risk of throboembolic complications hospitalized in nonsurgical departments, 23% of subjects received some form of prophylaxis; only 16% of them were given prophylaxis concordant with the guidelines. 18 Similarly, a small percentage of patients receiving prophylaxis -31%, was noted by Stark and Kilzer in the retrospective review of medical records of 100 patients. 19 The mean of prophylaxis use in Poland was 63%. This appears to be a better (but still not ideal) result than the findings presented in available data. With the frequency of contraindications of 10%, the optimal level of prophylaxis use should amount to about 90%. The percentage of patients receiving prophylaxis in intensive care units is close to the optimal level. A prospective study which assessed the frequency of antithrombotic prophylaxis use in 142 French and Canadian intensive care units confirmed that 92% of patients with indications and without contraindications received prophylaxis. 20 This is an important observation because patients hospitalized in intensive care units are a high risk group for VTE and simultaneously derive greater benefits from the antithrombotic prophylaxis. 21 The extent of observance of the guidelines among teams working in intensive care units does not differ List of centers participating in the registry is presented in Appendix.
is that in the group of patients hospitalized because of heart failure there is a significantly higher percentage of patients using prophylaxis. If true, this should be improved by appropriate education. This is of great importance as low doses of heparins used in VTE prophylaxis provide an optimal compromise between the effectiveness and the risk of hemo rrhagic complications. Higher doses may unfavorably shift this balance towards an increased risk of bleedings. On the other hand, too low doses (i.e. 20 mg of enoxaparin daily) appeared to be ineffective in antithrombotic prophylaxis in the MEDENOX population.
It is inter esting that hemo rrhagic complications occurred in <1% of patients receiving antithrombotic prophylaxis. This number is closer to the frequency of severe (massive) bleedings observed in randomized clinical studies with low doses of low-molecular-weight heparins; however, it is definitely less common than all bleedings, which range from 7 to 9%. 27 Practicing physicians may take a situation requiring performance of additional tests, blood transfusion or medical intervention for "hemorrhagic complication", which would approximately correspond to the definition of severe hemo rrhagic complication in clinical studies. Less severe bleedings (i.e. epistaxis) are rarely recognized as complications by practicing physicians. However, it should be remembered that the reporting method of hemo rrhagic complications in the registry was completely different from that commonly used in controlled clinical trials. study limitations In the following study only a subgroup of patients with, according to international guidelines, indications for antithrombotic prophylaxis was analyzed. As a result evaluation of the frequency of overuse of antithrombotic prophylaxis in patients without indications was impossible.
In evaluation of the frequency of prophylaxis use in particular provinces, a potential falsification of the real situation may arise from different numbers of centers participating in the registry within particular provinces and resulting from this various numbers of patients enrolled in the registry.
An appropriate use of antithrombotic prophylaxis in the MEDENOX population is of crucial epidemio logical importance, as this group constitutes about 31% of all patients hospitalized in inter nal medicine departments. The VTE prophylaxis is still rarely used in the group of non-surgical department patients, especially in general medicine departments. Disparities in the frequency of prophylaxis use between particular provinces are striking. Administered doses are in many cases different from those recommended by the guidelines.
